Medicxi Announces $40m investment in D3 Bio
- Investment will support development of a differentiated pipeline in oncology
- Most advanced asset is D3S-001 with potential to be a best-in-class KRAS G12C inhibitor
- Data on lead asset D3S-001 to be presented at AACR on 8 April 2024
8 April 2024, London, Geneva & Jersey: Medicxi, a leading European life sciences investment firm, today announces an investment of $40 million in D3 Bio, a biotechnology company based in Shanghai, China. D3 Bio is focused on the discovery, development, and registration of innovative medicines in oncology and immunology. The investment will accelerate the development of D3 Bio’s innovative pipeline of oncology compounds. Francesco De Rubertis, Partner at Medicxi, will join the Board of D3 Bio.
